Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$9.48 -4.0%	$6.91	$4.50 ▼ $21.94	$39.95M	0.76	52,847 shs	52,323 shs
GBIO Generation Bio	$6.66 +0.8%	$4.12	$3.00 ▼ $29.40	$44.52M	2.67	825,900 shs	762,770 shs
GNPX GENPREX	$0.22 -4.1%	$0.26	$0.20 ▼ $3.97	$7.46M	-0.53	1.06 million shs	857,569 shs
SCYX SCYNEXIS	$0.80 -5.1%	$0.76	$0.66 ▼ $1.79	$32.98M	1.64	204,563 shs	137,084 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	-4.05%	+19.40%	+29.51%	+23.92%	+4.58%
GBIO Generation Bio	+0.76%	+60.48%	+56.34%	+74.67%	-71.42%
GNPX GENPREX	-4.09%	-2.44%	-27.17%	-12.62%	-70.42%
SCYX SCYNEXIS	-5.15%	-8.39%	+5.47%	+1.47%	-51.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FGEN FibroGen	4.609 of 5 stars	3.3	5.0	4.7	2.2	3.3	0.6
GBIO Generation Bio	3.2989 of 5 stars	3.3	3.0	0.0	2.1	3.3	1.3
GNPX GENPREX	1.4724 of 5 stars	0.0	3.0	4.7	2.5	0.0	0.6
SCYX SCYNEXIS	1.5655 of 5 stars	0.0	5.0	0.0	3.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FGEN FibroGen	2.50	Moderate Buy	$43.00	353.59% Upside
GBIO Generation Bio	2.67	Moderate Buy	$37.33	460.56% Upside
GNPX GENPREX	0.00	N/A	N/A	N/A
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GNPX, GBIO, FGEN, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$7.00 ➝ $7.00
8/13/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/7/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00
7/18/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $70.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FGEN FibroGen	$29.62M	1.29	N/A	N/A	($50.08) per share	-0.19
GBIO Generation Bio	$19.89M	2.26	N/A	N/A	$8.03 per share	0.83
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.15 per share	N/A
SCYX SCYNEXIS	$2.63M	11.89	N/A	N/A	$1.45 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FGEN FibroGen	-$47.58M	-$0.38	N/A	N/A	N/A	-3.86%	N/A	-27.34%	N/A
GBIO Generation Bio	-$131.67M	-$10.82	N/A	N/A	N/A	-341.12%	-91.07%	-33.65%	N/A
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-664.65%	-370.18%	8/15/2025 (Estimated)
SCYX SCYNEXIS	-$21.29M	-$0.40	N/A	16.03	N/A	-599.05%	-41.02%	-26.14%	8/14/2025 (Estimated)

Latest GNPX, GBIO, FGEN, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GNPX GENPREX	-$0.71	-$0.17	+$0.54	-$0.17	N/A	N/A
8/13/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	-$0.14	+$0.09	-$0.14	$0.15 million	$1.36 million
8/12/2025	Q2 2025	GBIO Generation Bio	-$2.80	-$3.12	-$0.32	-$3.12	$2.51 million	$0.77 million
8/11/2025	Q2 2025	FGEN FibroGen	-$2.25	-$3.38	-$1.13	-$1.88	$2.88 million	$1.30 million
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FGEN FibroGen	N/A	1.04	1.98
GBIO Generation Bio	N/A	7.51	8.43
GNPX GENPREX	N/A	1.94	1.94
SCYX SCYNEXIS	N/A	5.83	5.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FGEN FibroGen	72.71%
GBIO Generation Bio	95.22%
GNPX GENPREX	14.05%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
FGEN FibroGen	3.07%
GBIO Generation Bio	21.80%
GNPX GENPREX	0.44%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
GBIO Generation Bio	150	6.74 million	5.27 million	Optionable
GNPX GENPREX	20	33.15 million	33.00 million	No Data
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable

GNPX, GBIO, FGEN, and SCYX Headlines

Recent News About These Companies

Scynexis reports Q2 EPS (14c), consensus (19c)

August 14 at 9:17 AM | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14 at 9:17 AM | finanznachrichten.de

SCYNEXIS Reports Improved Financials Amidst Strategic Developments

August 14 at 9:17 AM | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 4:30 PM | globenewswire.com

SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday

August 13 at 2:50 AM | americanbankingnews.com

SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment

August 8, 2025 | msn.com

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, GBIO, FGEN, and SCYX Company Descriptions

FibroGen NASDAQ:FGEN

$9.48 -0.40 (-4.05%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$9.36 -0.12 (-1.22%)

As of 08/14/2025 07:03 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Generation Bio NASDAQ:GBIO

$6.66 +0.05 (+0.76%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.36 -0.30 (-4.43%)

As of 08/14/2025 07:58 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GENPREX NASDAQ:GNPX

$0.22 -0.01 (-4.09%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.22 +0.00 (+1.85%)

As of 08/14/2025 07:58 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

SCYNEXIS NASDAQ:SCYX

$0.80 -0.04 (-5.15%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.42%)

As of 08/14/2025 07:31 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time